SUPG Supergen, Inc. (MM)

DUBLIN, Calif., Sept. 18 /PRNewswire-FirstCall/ -- SuperGen, Inc. (NASDAQ:SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced that James S. Manuso, Ph.D., President and Chief Executive Officer, is scheduled to present at the UBS Global Life Sciences Conference on Thursday, September 25, 2008, at The Grand Hyatt New York. SuperGen's presentation at the UBS Global Life Sciences Conference is scheduled to begin at 12:30 p.m. EDT (9:30 a.m. PDT). A live webcast of the presentation will be available on the investor relations section of the Company's Web site at http://www.supergen.com/. A webcast replay of the presentation will be available shortly following the live event. About SuperGen Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery and development of novel cancer therapies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com/. Contacts: SuperGen, Inc. Dorland Global Public Relations Timothy L. Enns Michael Beckerich (Media) SVP, Corporate Communications Tel: (212) 677-7632 & Business Development Tel: (925) 560-0100 Email: Mary M. Vegh Manager, Investor Relations Tel: (925) 560-2845 E-mail: DATASOURCE: SuperGen, Inc. CONTACT: Timothy L. Enns, SVP, Corporate Communications & Business Development, +1-925-560-0100, , or Mary M. Vegh, Manager, Investor Relations, +1-925-560-2845, , both of SuperGen, Inc.; or Media, Michael Beckerich of Dorland Global Public Relations for SuperGen, Inc., +1-212-677-7632, Web site: http://www.supergen.com/

Copyright